Yamamoto Akiko, Okada Annabelle A, Nakayama Makiko, Yoshida Yumiko, Kobayashi Hiroaki
Department of Ophthalmology, Kyorin University Hospital, Kyorin University School of Medicine, Tokyo, Japan.
Ophthalmologica. 2017;237(3):139-144. doi: 10.1159/000458538. Epub 2017 Mar 4.
The aim of this study was to investigate the 1-year outcomes of treat-and-extend aflibercept for exudative age-related macular degeneration (AMD) in Japan.
Clinical records of 67 patients (67 eyes) were reviewed. Monthly aflibercept was administered until resolution of exudation and maximal reduction of pigment epithelial detachment. Injection intervals were extended by 2-week units up to 12 weeks if no exudation was observed and shortened for recurrence.
Mean best-corrected visual acuity (logarithm of the minimum angle of resolution) improved from 0.29 to 0.14 at 12 months (p < 0.0001). Mean central retinal thickness decreased from 430 μm to 236 μm at 12 months (p < 0.0001). Fifty-nine eyes (88.0%) achieved a dry macula with a mean of 8.3 injections by study end. The injection interval was extended to 10 weeks in 44.8% and to 12 weeks in 17.9% of eyes.
At 1 year, good outcomes were obtained using treat-and-extend aflibercept for exudative AMD in Japan.
本研究旨在调查在日本采用治疗并延长给药间隔方案使用阿柏西普治疗渗出性年龄相关性黄斑变性（AMD）的1年疗效。
回顾了67例患者（67只眼）的临床记录。每月给予阿柏西普，直至渗出消退且色素上皮脱离最大程度减轻。如果未观察到渗出，注射间隔以2周为单位延长至最长12周，若复发则缩短注射间隔。
12个月时，平均最佳矫正视力（最小分辨角对数）从0.29提高至0.14（p < 0.0001）。12个月时，平均中心视网膜厚度从430μm降至236μm（p < 0.0001）。截至研究结束时，59只眼（88.0%）实现黄斑干性转归，平均注射8.3次。44.8%的眼注射间隔延长至10周，17.9%的眼延长至12周。
在日本，采用治疗并延长给药间隔方案使用阿柏西普治疗渗出性AMD，1年时取得了良好疗效。
